These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 1653204

  • 1. Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli.
    Reguera JA, Baquero F, Pérez-Díaz JC, Martínez JL.
    J Antimicrob Chemother; 1991 May; 27(5):569-75. PubMed ID: 1653204
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L, Picón E, Morillo C, Hernández JR, Docobo F, Pachón J, Rodríguez-Baño J, Pascual A.
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [Abstract] [Full Text] [Related]

  • 4. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S, Marre R.
    Infection; 1991 Feb; 19(2):106-9. PubMed ID: 1646771
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Activity of clavulanate combinations against TEM-1 beta-lactamase-producing Escherichia coli isolates obtained in 1982 and 1989.
    Seetulsingh PS, Hall LM, Livermore DM.
    J Antimicrob Chemother; 1991 Jun; 27(6):749-59. PubMed ID: 1938685
    [Abstract] [Full Text] [Related]

  • 7. Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations.
    Bonfiglio G, Livermore DM.
    J Antimicrob Chemother; 1993 Sep; 32(3):431-44. PubMed ID: 8262865
    [Abstract] [Full Text] [Related]

  • 8. Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents.
    Vanjak D, Muller-Serieys C, Picard B, Bergogne-Berezin E, Lambert-Zechovsky N.
    Eur J Clin Microbiol Infect Dis; 1995 Nov; 14(11):972-8. PubMed ID: 8654448
    [Abstract] [Full Text] [Related]

  • 9. Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors.
    Thomson CJ, Amyes SG.
    J Antimicrob Chemother; 1993 May; 31(5):655-64. PubMed ID: 8392995
    [Abstract] [Full Text] [Related]

  • 10. Beta-lactamase inhibitors and Acinetobacter spp.
    Eng RH, Smith SM, Cherubin CE.
    J Antimicrob Chemother; 1990 Sep; 26(3):449-51. PubMed ID: 2172200
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
    Blazquez J, Baquero MR, Canton R, Alos I, Baquero F.
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2059-63. PubMed ID: 8257123
    [Abstract] [Full Text] [Related]

  • 13. Activity of amoxycillin/clavulanate against beta-lactamase-producing Escherichia coli and Klebsiella spp.
    Roy C, Segura C, Torrellas A, Reig R, Teruel D, Hermida M.
    J Antimicrob Chemother; 1989 Nov; 24 Suppl B():41-7. PubMed ID: 2691485
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.
    Jacobs MR, Spangler SK, Appelbaum PC.
    J Antimicrob Chemother; 1990 Sep; 26(3):361-70. PubMed ID: 2228827
    [Abstract] [Full Text] [Related]

  • 16. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
    Docobo-Pérez F, López-Cerero L, López-Rojas R, Egea P, Domínguez-Herrera J, Rodríguez-Baño J, Pascual A, Pachón J.
    Antimicrob Agents Chemother; 2013 May; 57(5):2109-13. PubMed ID: 23439636
    [Abstract] [Full Text] [Related]

  • 17. Use of beta-lactam/beta-lactamase-inhibitor combinations as antimycobacterial agents.
    Prabhakaran K, Harris EB, Randhawa B, Adams LB, Williams DL, Hastings RC.
    Microbios; 1993 May; 76(309):251-61. PubMed ID: 8302203
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro].
    Blahová J, Hupková M, Krcméry V.
    Cas Lek Cesk; 1995 Sep 06; 134(17):558-61. PubMed ID: 7553760
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.